Obsessive-Compulsive Disorder (OCD) Clinical Trial
Official title:
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01949753 -
Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder
|
Phase 2 | |
Recruiting |
NCT04042038 -
Neural Predictors and Neural Changes Associated With Cognitive Behavior Therapy for Obssesive Compulsive Disorder
|
N/A | |
Completed |
NCT02867449 -
Metacognitive Therapy for Obsessive-Compulsive Disorder
|
N/A | |
Completed |
NCT01368510 -
Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder
|
N/A | |
Not yet recruiting |
NCT05422469 -
OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial
|
N/A | |
Active, not recruiting |
NCT03300947 -
Psilocybin for Treatment of Obsessive Compulsive Disorder
|
Phase 1 | |
Recruiting |
NCT02773082 -
Reclaimâ„¢ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)
|
N/A | |
Not yet recruiting |
NCT06360991 -
DBS for Treatment-resistant Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT03605316 -
Deep Electrical Neuromodulation in Obsessive-compulsive Disorder
|